SCHEMBL20424336

SCHEMBL20424336

CCCCCCC(C=O)=Cc1ccc(C#N)cc1

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.67
▸ LMNA P02545 1/20 0.64
▸ TSHR P16473 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ FBP1 P09467 3/20 0.42
▸ MGLL Q99685 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ PGR P06401 1/20 0.36
▸ APP P05067 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20424334 1.00 TDP1 (0.67) TDP1LMNATSHRHSD17B10FBP1
SCHEMBL20424322 0.85 TDP1 (0.52) TDP1LMNATSHRHSD17B10FBP1
SCHEMBL20424323 0.85 TDP1 (0.52) TDP1LMNATSHRHSD17B10FBP1
SCHEMBL29963954 0.85 TDP1 (0.52) TDP1LMNATSHRHSD17B10FBP1
SCHEMBL17444737 0.84 TDP1 (0.64) TDP1LMNAFBP1
SCHEMBL17444732 0.82 TDP1 (0.74) TDP1LMNATSHRSMN1; SMN2ALDH1A1
SCHEMBL565590 0.82 TDP1 (0.74) TDP1LMNATSHRSMN1; SMN2ALDH1A1
SCHEMBL565591 0.82 TDP1 (0.74) TDP1LMNATSHRSMN1; SMN2ALDH1A1
SCHEMBL20424330 0.81 TDP1 (0.72) TDP1LMNAKMT2AAPP
SCHEMBL17444740 0.81 TDP1 (0.72) TDP1LMNAMGLLSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115710181-A Compounds for reducing perception of malodour and uses thereof 凯姆克姆公司 2023-02-24 — — CN disclosed
US-20220378675-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM S.A. (BE) 2022-12-01 — — US disclosed
CN-110494413-B Compounds for reducing perception of malodour and uses thereof 凯姆克姆公司 2022-11-22 — — CN disclosed
EP-4059917-A2 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF ChemCom S.A. (BE) 2022-09-21 — — EP disclosed
US-11382848-B2 Compounds reducing malodour perception and the use thereof CHEMCOM S.A. (BE) 2022-07-12 — — US disclosed
EP-3573944-B1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM SA (BE) 2022-03-02 — — EP disclosed
WO-2018138369-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM S.A. (BE) 2018-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11382848-B2 Compounds reducing malodour perception and the use thereof OR51E2, OR10J3, SRD5A1 TDP1 4689/4885LMNA 4749/4885TSHR 808/4885
US-20220378675-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF OR51E2, OR10J3, SRD5A1 TDP1 4689/4885LMNA 4749/4885TSHR 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback